Not a good buy right now for an impatient investor: there is no Intellectia buy trigger (AI Stock Picker/SwingMax), and there are no near-term catalysts in the news flow.
Technicals are constructive (bullish MA stack, MACD > 0), but momentum is not accelerating (MACD histogram is contracting) and price is sitting between pivot support and nearby resistance.
Fundamentals are the bigger issue: Q3’25 showed a very large revenue decline YoY, which makes upside follow-through less reliable without a fresh catalyst.
Trend: Bullish structure with SMA_5 > SMA_20 > SMA_200, indicating an established uptrend across short/medium/long horizons.
Momentum: MACD histogram at 0.159 (above zero) but positively contracting → upside momentum is still positive but weakening.
RSI: RSI_6 at 59.8 (neutral-to-slightly-bullish), not signaling an oversold “must-buy” entry.
Levels: Pre-market 11.47 is above Pivot 11.03 (constructive). Key upside resistance at R1 12.298 then R2 13.082; downside supports at S1 9.762 then S2 8.978.
Pattern-based odds: Similar-pattern projection indicates modest upside bias (about +1.83% next day / +2.77% next week / +2.96% next month), but not a high-conviction surge signal.
Positive Catalysts
with Outperform/Buy maintained.
Neutral/Negative Catalysts
No news in the past week: lack of event-driven catalysts reduces the odds of an immediate breakout.
Financial headwind: Q3’25 revenue fell sharply (-41.4% YoY), which typically pressures valuation and limits multiple expansion.
Profitability trend appears to have deteriorated materially YoY (net income and EPS both down over 100% by the provided figures), raising questions about earnings quality/consistency.
Flow/positioning: Hedge funds and insiders are neutral (no strong “smart money” tailwind).
Financial Performance
Latest quarter: 2025/Q3.
Revenue: $59.887M, down -41.40% YoY (significant contraction).
Net income: $3.569M, down -129.73% YoY (material deterioration per provided data).
EPS: 0.51, down -129.14% YoY (material deterioration per provided data).
Gross margin: 74.56%, up +10.74% YoY (clear positive on efficiency/unit economics, but not enough to offset the revenue decline in the near term).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent direction: Ratings stayed positive while price targets were raised.
2025-11-12 (Noble Capital): PT raised to $15 from $12; kept Outperform; cites upwardly revised 2026 adj. EBITDA forecast post-Q3.
2025-11-11 (Canaccord): PT raised to $9 from $7; kept Buy; cites outperformance vs expectations and transformation execution.
Wall Street pros/cons view: Pros focus on transformation execution and margin/EBITDA trajectory; cons are dominated by the steep revenue decline and the need for continued proof that profitability can hold while sales stabilize.
Influential/political trading: No recent congress trading data available (last 90 days).
Wall Street analysts forecast BODI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BODI is 12 USD with a low forecast of 9 USD and a high forecast of 15 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast BODI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BODI is 12 USD with a low forecast of 9 USD and a high forecast of 15 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 9.990
Low
9
Averages
12
High
15
Current: 9.990
Low
9
Averages
12
High
15
Noble Capital
Michael Kupinski
Outperform
maintain
$12 -> $15
AI Analysis
2025-11-12
Reason
Noble Capital
Michael Kupinski
Price Target
$12 -> $15
AI Analysis
2025-11-12
maintain
Outperform
Reason
Noble Capital analyst Michael Kupinski raised the firm's price target on Beachbody Company to $15 from $12 and keeps an Outperform rating on the shares to reflect the firm's upwardly revised 2026 adjusted EBITDA forecast following the company's Q3 report.
Canaccord
Buy
maintain
$7 -> $9
2025-11-11
Reason
Canaccord
Price Target
$7 -> $9
2025-11-11
maintain
Buy
Reason
Canaccord raised the firm's price target on Beachbody Company to $9 from $7 and keeps a Buy rating on the shares. The firm said the company outperformed expectations in the quarter as it continued to progress through its significant transformation driven by strong execution and a more efficient operating model.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BODI
